Ketorolac trometamol [1] , a parenteral nonsteroidal anti-inflammatory drug (NSAID), is currently being assessed as a postoperative analgesic [2] . In animal models, ketorolac has analgesic, antipyretic, and anti-inflammatory actions attributed to prevention of prostaglandin synthesis by inhibition of the enzyme cyclooxygenase [3] , a mechanism of action common to all aspirin-like drugs [4] .
Ketorolac has compared favourably with opioids in studies of postoperative pain, and with other analgesics after minor surgery [5, 6] ; 30 mg was as effective as morphine 12 mg in relieving moderate to severe pain after major surgery [7, 8] . Infusions of ketorolac reduced morphine requirement after upper abdominal surgery [9] .
Ketorolac is a non-opioid analgesic and does not produce respiratory depression [10] , reduction of gastrointestinal motility [11] , addiction [12] , or psychomotor effects [13] , but NSAID have potential problems related to their mechanism of action. Prostaglandins have many physiological roles [14] , and NSAID may produce side effects including gastric and duodenal ulceration, bronchospasm and renal impairment. Also, platelet cyclo-oxygenase is essential for production of thromboxane A 2 which is an important mediator of aggregation and vasoconstriction-processes which constitute the primary haemostatic response to vessel injury. Other NSAID have been reported to increase surgical blood loss [15] . Ketorolac is known to inhibit platelet function in volunteers [16, 17] , but there is little information about its effect on surgical bleeding.
This study was designed to examine the efficacy and safety of multiple doses of i.m. ketorolac 30 mg compared with morphine 10 mg after cholecystectomy. The effect of ketorolac on operative blood loss, skin bleeding time and whole blood platelet aggregation was also observed.
PATIENTS AND METHODS
One hundred male and female patients undergoing elective cholecystectomy were studied. The investigation was approved by the local Ethics Committee and each subject gave written informed consent. Exclusion criteria were a history of ulcer disease, bleeding tendency, asthma, allergy, intolerance to aspirin, age less than 18 yr, recent administration of analgesia and abuse of drugs, alcohol or opioids.
Anaesthesia
Premedication was oral temazepam. Anaesthesia was induced with i.v. thiopentone and maintained with halothane, enfiurane or isoflurane in an oxygen-nitrous oxide mixture. The trachea was intubated after administration of suxamethonium. The lungs were ventilated artificially and vecuronium or atracurium given to achieve neuromuscular block; neostigmine with atropine was given to antagonize residual block. No analgesics were used other than study medication. Subcutaneous heparin 5000 iu at the time of premedication was given to all patients as prophylaxis against venous thrombosis.
Study design
A double-blind parallel dose comparison was made of two treatment groups: ketorolac 30 mg (n = 50) and morphine 10 mg (n = 50). Patients were allocated randomly to receive ketorolac or morphine in groups of 10. The two analgesics were supplied in identical 1-ml, amber coloured ampoules in boxes of eight, numbered 1 to 100. Each patient was allocated a study number, and received all eight doses from that box.
Administration of analgesia
The first dose was given into the vastus lateralis muscle at induction of anaesthesia. Doses were then given on patient demand, up to 2-hourly, with a maximum of six doses in 24 h. Each patient was permitted to receive eight doses of study medication during the study, which lasted up to 48 h. If analgesia was inadequate, rescue medication (morphine) was given at the discretion of the nurse, and the patient continued in the study.
Efficacy
Assessments were made on the second dose of study medication (immediately after surgery, day 1) and on a dose on the morning of the next day (day 2). The patient and an independent nurse observer scored pain intensity separately before injection, and pain intensity and pain relief at 0.5, 1,2, 3,4, 5 and 6 h. If the patient required further analgesia or fell asleep in the 6-h study period, the last score recorded was used for the remaining observation times.
Pain scores
Scores were made by the same nurse observer. The patients gave assessments by verbal response scores and visual analogue scales.
Pain intensity scores. Pain intensity was scored by the nurse and the patient on a four-point scale (0 = no pain; l=mild; 2 = moderate; 3 = severe). The patient also completed 10-cm visual analogue scales (0 = no pain, to 10 cm = worst possible pain).
Pain relief scores. The observer and the patient scored pain relief on a four-point scale (0 = no relief; 1 = slight; 2 = moderate; 3 = complete), and the patient completed visual analogue scales (0 = no relief, to 10 cm = complete relief).
Derived scores. Pain intensity differences (PID) were calculated by subtracting the scores from the baseline score. The seven PID from the 6-h observation periods were added together to give summed pain intensity differences (SPID). SPID were derived for the observer and patient for days 1 and 2. The visual analogue equivalent of SPID from the patient was calculated (visual analogue SPID). Total pain relief scores (PRtot) and the visual analogue equivalent (visual analogue PRtot) were calculated by adding the scores from each observation time.
Intervals between injections. We recorded the time in minutes between the second dose (immediately after surgery) and the next analgesic injection, as a further measure of efficacy.
Morning assessments. On the morning after surgery (day 2) and the next morning (day 3) the patient was asked if s/he had slept well, if pain control was satisfactory, and about any unpleasant dreams. Oral temperature was noted.
Final assessment. At the end of the study, both patient and observer independently gave an overall opinion of analgesia as very good/good/ fair/poor.
Oral intake and i.v. fluids
The time in hours was recorded from the end of surgery to established oral intake and to removal of the i.v. infusion.
Completion rates and early withdrawal
Each subject completed the study if all eight doses of medication over days 1 and 2 were received. Completion rates were compared between the groups, and reasons for withdrawal noted.
Injection site discomfort
Some NSAID produce pain and muscle damage when injected [13] . To assess if ketorolac produced this side effect the nurse noted any abnormality at the injection site. The subject rated pain on injection as none/minimal/ moderate/severe.
Adverse events. All were recorded, and venous blood was sampled for haematological and biochemical analysis before and after the study period.
Haemostasis and blood loss
In all subjects, operative blood loss was estimated by weighing swabs. Within the randomization schedule in 10 subjects from each group, skin bleeding time was recorded before surgery and 1 h after the first dose of study medication. In 10 of these 20 subjects, platelet function tests were performed also at the same time. None of these 20 subjects was a cigarette smoker.
Skin bleeding times were recorded in duplicate on the forearm by the modified method of Ivy [18, 19] using a Simplate II bleeding time device to standardize the length and depth of incision. Bleeding time was taken for the two incisions and the mean time recorded. The upper limit of normal using this technique is 10 min [19] .
In five subjects in each group, platelet ag-1 gregation was studied in vitro using a ClayAdams Ultra-Flo whole blood platelet counter [20, 21] . Spontaneous, collagen 2 ug ml" 1 -induced (Semmelweiss), and arachidonic acid 0.5 mmol litre~'-induced (Sigma) aggregation were observed. Whole venous blood was anticoagulated with 3.8% trisodium citrate. From each sample, a red cell count was first determined and dialled into the whole blood platelet counter. A 10-uI aliquot was withdrawn and the baseline platelet count determined (100%). The aggregating agent, if used, was added and the sample stirred at a constant 1000 r.p.m. and 37 °C. Further aliquots were taken at 5 and 10 min for spontaneous aggregation, and at 1, 3 and 5 min for collagenand arachidonic acid-induced aggregation. The platelet count at each sample time was determined as a percentage of the baseline count. Collagenand arachidonic acid-induced aggregation depend to a large extent on thromboxane production, but spontaneous aggregation does not.
Statistical analysis
In comparing the two analgesics, the most important measurement of efficacy was SPID. As the pain scores were on an ordered four-point scale, PID at each assessment could be -3 to 3. SPID over 6 h (seven assessments) could range from -21 to 21, with a mean of zero and SD of approximately 7. Taking a significance level a of 5%, a difference between the analgesics in SPID of 4 (approximately 10%) could be detected with a power of 80% if the total sample size was 100 patients.
For demographic data mean (SEM) is given, and between group comparisons made using an unpaired t test. For other data median and range are given, and non-parametric statistical tests used. Categorical data were analysed using Fisher's exact or Pearson's chi-square test. Ordinal and interval data were analysed using the MannWhitney U test for unpaired and the Wilcoxon signed rank test for paired data. P < 0.05 was considered significant.
RESULTS
The groups were similar with respect to sex, age, height, weight, position of incision and duration of surgery (table I) .
Efficacy (table II) Baseline pain intensity. Pain intensity was similar for the two groups on days 1 and 2. The patients scored pain as severe on day 1 and moderate on day 2.
Pain intensity scores. Observer and patient SPID were significantly less for ketorolac than for morphine on day 1. On day 2 ketorolac and morphine gave similar results. Visual analogue SPID was less for ketorolac on day 1, but the difference was not statistically significant. On day 2 there was no difference.
Pain relief scores. Observer and patient PRtot were significantly less for ketorolac on day 1, but on day 2 there was no difference.
Visual analogue PRtot showed no difference between the drugs on each day. (table III) . After the second dose of study medication, patients receiving ketorolac required repeat analgesia sooner than those receiving morphine. In the first 24 h of the study the ketorolac group required more rescue medication than the morphine group. In the second 24 h there was no difference between the groups.
Intervals between injections and rescue morphine
Morning assessments (table IV) . The patients in the two groups reported similar satisfaction with overnight sleep and pain relief. There was no difference in the incidence of psychological disturbances or pyrexia.
Final assessment (table V) . There was no statistical difference between the overall opinions of the patients or observers of the study medi- (table V) . The time until oral intake recommenced was not different between the gfoups, but the morphine group received i.v. fluids for longer.
Completion rates and early withdrawal (table V). •
The completion rate was similar for the two groups, but more patients withdrew in the ketorolac group. The most common reason for early withdrawal was that parenteral analgesia was no longer required and oral therapy was started. Failure of analgesia accounted for seven and two withdrawals from the ketorolac and morphine groups, respectively.
Injection site abnormalities and pain (table V).
There was no difference in the incidence of injection site abnormality or pain on injection between the groups.
Adverse events. Ketorolac produced more nausea (P = 0.005) and vomiting (P = 0.05) on the day of operation, but not on the day after (P = 0.73, and 0.85, respectively). Morphine was associated with a greater incidence of drowsiness on days 1 (P = 0.0001) and 2 (P = 0.007).
Two patients from the ketorolac group and four from the morphine group were withdrawn because of severe adverse events. In the ketorolac group, one patient was returned to theatre because of continuing blood loss; an obvious source was controlled. Another of the ketorolac group developed a chest infection. Two of the morphine group had excessive postoperative blood loss. One was returned to theatre, but no obvious bleeding vessel was found; the other required a blood transfusion only. Two of the morphine group developed chest infections; one also experienced severe drowsiness which was treated with naloxone. No other serious adverse events were reported. No abnormal changes were detected on biochemical or haematological analysis of blood.
Haemostasis and blood loss (table VI)
Operative blood loss. There was no statistical difference in the blood loss of the two groups (P = 0.5); the median loss of the ketorolac group was 192 ml (range 20-580 ml), and the morphine group 162 ml (25-950 ml). Skin bleeding time. This was prolonged significantly by ketorolac from a median of 222 s to 299 s. After ketorolac, the longest bleeding time was 369 s-an increase of 214 compared with control, but within the normal upper limit of 600 s. The morphine group showed no change in bleeding time.
Platelet aggregation. Spontaneous platelet aggregation was unchanged after ketorolac. Collagen-and arachidonic acid-induced aggregation tended to be reduced by ketorolac, but statistical significance was approached only for collagen-induced aggregation at 3 and 5 min. There was no change in the morphine group.
DISCUSSION
After cholecystectomy, ketorolac 30 mg gave poor analgesia in the immediate postoperative period when compared with morphine 10 mg, but on the next day the effect of the two drugs was similar. This was demonstrated by observations of pain intensity, pain relief, time to next injection, and overall assessment of analgesia. The baseline pain intensity in the immediate postoperative period was severe, and the next day it was moderate. Our findings suggest that an i.m. dose of ketorolac 30 mg is sufficient for the relief of moderate, but not severe pain.
Other observers found that ketorolac 30 mg was at least as effective as morphine 12 mg in relieving moderate to severe pain after various operations, including major surgery [7, 8] . As these were single-dose studies performed up to 2 days after surgery, they should be compared with our day 2 results, to which they are similar.
Our conclusion that ketorolac is unsuitable for the relief of severe pain is similar to that from studies on the analgesic effect of a parenteral formulation of aspirin. Lysine acetyl salicylate is a poor analgesic compared with morphine as a bolus in the immediate postoperative period [22] , but equivalent to morphine when given as an infusion over a period of time [23] .
Although ketorolac was a poor analgesic in the immediate postoperative period, the ketorolac group expressed overall satisfaction with their analgesia, and required only a small dose of rescue morphine (10 mg) in the first 24 h and none the next day. Such results may indicate that the quality of ketorolac analgesia became similar to that of morphine after the initial postoperative period. A morphine sparing effect of ketorolac after abdominal surgery has been documented before [9] .
Ketorolac does not inhibit gut motility [11] , and in this study the patients receiving ketorolac required i.v. fluids for a shorter time, although the time to oral intake did not differ between groups. This may be important because ketorolac will also be available as tablets which could be used when the patient is able to take fluids. It was noted that many patients in this study required parenteral analgesia for only a short time after cholecystectomy.
I.m. ketorolac did not produce more injection site pain or abnormalities than morphine. Ketorolac given as repeated i.m. injections does not increase serum concentrations of creatine phosphokinase, but diclofenac does [13] . The muscular discomfort produced by injections of diclofenac may not be a problem with ketorolac.
With the exception of six patients, adverse events were minor. Ketorolac was associated with more nausea and vomiting on the day of operation, and drowsiness and sedation were persistent problems with morphine, as could be predicted from studies on psychomotor effects of ketorolac and opioids [13] . No serious side effects resulted from repeated administration of ketorolac over 2 days. In particular, there were no untoward gastrointestinal or renal effects. As the adverse renal effects of NSAID are serious and well documented [24] , more detailed studies of the effect of ketorolac on kidney function are required before the intraoperative use of the drug can be recommended.
Ketorolac 30 mg did not increase operative blood loss, although it prolonged skin bleeding time and tended to inhibit platelet aggregation, as observed in volunteer studies [16, 17] . The effect was similar to that of a single dose of aspirin and may be clinically insignificant because none of the bleeding times was abnormal after ketorolac [25] . Nevertheless the effect of NSAID on operative blood loss is still unclear. Blood loss is increased by indomethacin after hysterectomy [15] , but not by diclofenac after gynaecological laparotomy [26] or transurethral prostatectomy [27] . As indomethacin, diclofenac and ketorolac have the same mechanism of action, a similar effect on blood loss could have been expected. The surgical procedure and the dose of NSAID could be important, and some patients may react excessively if they have a subclinical haemostatic defect [28] .
Ketorolac is therefore a clinically useful parenteral analgesic after upper abdominal surgery and 30 mg i.m. is adequate for relief of pain of moderate intensity.
